Abevmy Market Report 2026

Abevmy Market Overview

• The Abevmy market growth in the historic period has been driven by high cost burden of originator biologics, rising global cancer incidence • Market expansion is supported by expanding biosimilar penetration in oncology, growing demand for affordable cancer therapies • Growth Driver: Rising Cancer Incidence Driving Growth Of The Abevmy Market • Market Trend: Biosimilars Driving Innovation And Accessibility In The Abevmy Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Abevmy Market?

Abevmy is a biosimilar version of the cancer drug bevacizumab, developed to offer a more affordable alternative while maintaining similar efficacy and safety. It works by targeting vascular endothelial growth factor (VEGF), a protein responsible for the formation of blood vessels that supply tumors with oxygen and nutrients. By inhibiting VEGF, Abevmy helps to prevent the growth of new blood vessels (angiogenesis), thereby limiting tumor growth and spread. The main doses in the abevmy market are 100mg and 400mg. The 100 mg dose of abevmy is a specific formulation designed for patients requiring treatment for various cancers. The various diseases include cancer and eye diseases, and distribution channels including direct tender, hospital pharmacy, retail pharmacy, and online pharmacy. The end users encompass hospitals, cancer supportive centers, academic and research institutes, and home healthcare.

What Is The Abevmy Market Growth Forecast?

The growth in the forecast period can be attributed to expanding biosimilar penetration in oncology, growing demand for affordable cancer therapies, increasing government support for biosimilars, rising oncology patient pool, broader tender based procurement adoption. Major trends in the forecast period include increasing adoption of bevacizumab biosimilars, rising use in cost sensitive oncology treatments, growing preference for hospital based biosimilar switching, expansion of anti angiogenic therapies in oncology, greater regulatory support for biosimilar approvals.

Global Abevmy Market Segmentation

1) By Dose: 100mg, 400mg 2) By Diseases: Cancer, Eye Diseases 3) By Distribution Channel: Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy 4) By End User: Hospitals, Cancer Supportive Centers, Academic And Research Institutes, Home Healthcare

What Is The Driver Of The Abevmy Market?

The increasing prevalence of cancer is expected to propel the growth of the abevmy market going forward. Cancer is influenced by a variety of factors, which can be broadly categorized into lifestyle choices, environmental exposures, and genetic predispositions. The increasing prevalence of cancer is due to a combination of factors, including an aging population, lifestyle changes such as poor diet, lack of physical activity, smoking, and alcohol consumption, as well as environmental exposures to carcinogens. Abevmy works by inhibiting vascular endothelial growth factor (VEGF), which reduces the formation of blood vessels that supply tumors with oxygen and nutrients, thus hindering their growth and spread. For instance, in February 2025, according to the American Cancer Society, a US-based non-profit cancer advocacy organization, in 2025, an estimated 9,550 children (ages 0 to 14 years) and 5,140 adolescents (ages 15-19 years) will be diagnosed with cancer, and 1,050 children and 600 adolescents will die from the disease. Therefore, the increasing prevalence of cancer is driving the abevmy industry.

Key Players In The Global Abevmy Market

Major companies operating in the abevmy market are Biocon Biologics Ltd., Viatris Inc.

Global Abevmy Market Trends and Insights

Major companies operating in the abevmy (bevacizumab biosimilar) market are focusing on developing biosimilars to expand access to affordable biologic treatments, address unmet medical needs, and reduce healthcare costs. Biosimilars aim to provide cost-effective alternatives to originator biologics while maintaining similar efficacy, safety, and quality. For instance, in June 2023, Enzene Biosciences, an India-based biotech company specializing in biosimilars and biologics CDMO services, launched Bevacizumab, a biosimilar of Avastin. The product is manufactured at Enzene’s Pune facility using their patented continuous manufacturing process, which significantly lowers production costs and carbon emissions. The biosimilar, a recombinant humanized monoclonal IgG1 antibody targeting vascular endothelial growth factor (VEGF), works by binding to VEGF and inhibiting its receptor interaction, thereby preventing tumor growth and proliferation of cancerous cells in affected patients.

What Are Latest Mergers And Acquisitions In The Abevmy Market?

In February 2024, Biocon Biologics, an India-based company that manufactures Abevmy, which is a biosimilar of Bevacizumab (Roche's Avastin), partnered with Sandoz Australia to expand the market reach of its oncology biosimilars by leveraging Sandoz’s established commercial and distribution network in Australia. Sandoz Australia is an Australia-based provider of generic pharmaceuticals and biosimilars, offering a wide portfolio across therapeutic segments to hospitals, clinics, and pharmacies.

Regional Insights

North America was the largest region in the abevmy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Abevmy Market?

The abevmy market consists of sales of intravenous (IV) infusion. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Abevmy Market Report 2026?

The abevmy market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the abevmy industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.